Accurate Classification System for Patients With COVID-19 Pneumonitis

Pneumonitis Clinical Trial

Official title:

Accurate Classification System for Patients With COVID-19 Based on Prognostic Nomogram

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04302688
• Other study ID #: COVID-19 WU1
• Status: Completed
• Start date: December 10, 2019
• Est. completion date: March 4, 2020

Study information

• Verified date: March 2020
• Source: Renmin Hospital of Wuhan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The COVID-19 has a clustering morbidity trend and older people with chronic diseases are more likely to die, such as chronic renal insufficiency and chronic cardiovascular disease. We set up a COVID-19 pneumonia grading scale. The COVID-19 score system was validated to predict the clinical outcome of a patient.

Description:

1. First we collect the medical records, according to the time sequence, the patients were divided into two groups, one is the model group, and the other is the validate group.

2. Responsible for the risk factor of regression equation according to the model. The patients were divided into three groups according to their total score of risk responsibility.

3. Compared with SEPSIS and CURB-65 grading system with the grading system we established.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 669
• Est. completion date: March 4, 2020
• Est. primary completion date: February 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with novel coronavirus pneumonia should be examined and diagnosed by CT and swab test of viral nucleic acid.

Exclusion Criteria:

• Patients who should have died during the course of the disease, but the cause of death was unrelated to viral pneumonia.

• Suspected patient review refers to the negative nucleic acid test.

Related Conditions & MeSH terms

• Pneumonia
• Pneumonitis

Locations

Country	Name	City	State
China	Renmin Hospital of Wuhan University	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Renmin Hospital of Wuhan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival status	survival status as of February 24, 2020	10 December 2019 to 10 February 2020